HUTCHMED (China) Limited has dosed the first patient in the Phase Ia segment of its global, first-in-human clinical study evaluating HMPL-A830, an antibody-targeted therapy conjugate (ATTC) for patients with unresectable, advanced or metastatic solid tumors. The initial administration took place in China on 24 September 2026.
HMPL-A830 combines a selective, potent small-molecule inhibitor of Kirsten rat sarcoma (KRAS) with an anti-epidermal growth factor receptor (EGFR) monoclonal antibody. The construct is designed to deliver the KRAS inhibitor directly to EGFR-expressing tumors while concurrently blocking EGFR and KRAS signaling. Colorectal, pancreatic and lung cancers—tumor types with KRAS alterations in up to 44%, 89% and 34% of cases respectively—represent key target indications.
Study design • Type: Multicenter, open-label Phase I trial (ClinicalTrials.gov ID: NCT07718581). • Current phase: Ia dose-escalation to determine maximum tolerated dose and recommended expansion dose. • Next step: Dose-expansion/optimization to further assess safety, tolerability and preliminary anti-tumor activity in selected solid tumors. • End-points: Safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy.
Strategic collaboration with GSK On 3 September 2026, HUTCHMED Limited, a subsidiary of HUTCHMED, entered an exclusive development and licence agreement with a subsidiary of GSK plc. The GSK entity gains rights to develop and commercialise HMPL-A830 worldwide, excluding Mainland China, Hong Kong, Macau and Taiwan. HUTCHMED retains responsibility for the ongoing global Phase I programme, while GSK will lead subsequent clinical development and commercial activities in the licensed territories. Completion of the agreement remains subject to customary closing conditions, including antitrust clearances.
ATTC platform overview HUTCHMED’s ATTC technology links monoclonal antibodies with proprietary small-molecule inhibitor payloads, aiming to achieve dual mechanisms of action and improved safety compared with traditional cytotoxin-based antibody-drug conjugates. By enabling tumor-specific payload delivery and simultaneous target inhibition, the platform seeks to enhance efficacy and durability while mitigating systemic toxicity.
Regulatory considerations Forward-looking statements in the announcement highlight customary risks associated with clinical development, regulatory approvals and transaction closings. The company emphasises that actual outcomes may differ materially from current expectations and provides no assurances regarding future performance.
Corporate profile HUTCHMED is a commercial-stage biopharmaceutical company dual-listed on Nasdaq, AIM and the Hong Kong Stock Exchange. The group focuses on discovering, developing and commercialising targeted therapies and immunotherapies for oncology and immunological diseases, with four medicines already marketed in China and one approved in major global markets.